Background 

Women receiving chemotherapy for gynecologic cancer (GC) experience severe symptoms with associated functional changes. Understanding day-to-day symptom and function variation within and across chemotherapy treatment cycles could inform improved symptom management, but such studies are rare and may be infeasible in clinical care.

Objective 

The aim of this study was to evaluate feasibility and acceptability of daily symptom monitoring combined with objective and self-reported functional assessments every 21 days during active chemotherapy for GC.

Methods 

Thirty women enrolled in a prospective observational study during first-line chemotherapy completed a daily symptom and falls diary during their entire chemotherapy treatment period. Patient-reported outcomes and objective symptom and function testing were assessed before each chemotherapy appointment. Study outcomes included accrual and attrition rates, completion of study assessments, and qualitative perceptions of study participation.

Results 

Participants were 92% White, 60% had high school or higher education, 68% were married/partnered, and 62% had stage III or IV cancer at diagnosis. The study had an 83% accrual rate, 6.6% early withdrawal rate, and 17% total attrition rate. Missing assessments for prechemotherapy patient-reported outcomes and objective assessments ranged from 27% to 35% and 35% to 47% respectively, with a general decrease across cycles. Daily diary completion rate was 83% overall. Participants rated study participation positively.

Conclusions 

Intensive daily symptom and function monitoring was feasible and acceptable to GC patients and may provide a sense of symptom controllability.

Implications for Practice 

Daily symptom and function monitoring in research studies may provide patients with information to support symptom discussions with the clinical team. Future work should develop proactive symptom management interventions using personalized symptom trajectories.

中文翻译：

---

对于接受妇科癌症一线化疗的女性来说，每日强化症状和功能监测是可行和可接受的

背景 

接受妇科癌症 (GC) 化疗的妇女会出现严重的症状以及相关的功能变化。了解化疗治疗周期内和之间的日常症状和功能变化可以改善症状管理，但此类研究很少见，在临床护理中可能不可行。

客观的 

本研究的目的是评估每日症状监测的可行性和可接受性，并在积极化疗期间每 21 天结合客观和自我报告的功能评估来评估 GC。

方法 

在一线化疗期间参加一项前瞻性观察研究的 30 名女性在整个化疗治疗期间完成了每日症状和跌倒日记。在每次化疗预约之前评估患者报告的结果以及客观症状和功能测试。研究结果包括应计和流失率、研究评估的完成以及对研究参与的定性看法。

结果 

参与者有 92% 是白人，60% 有高中或高等教育，68% 已婚/伴侣，62% 在诊断时患有 III 期或 IV 期癌症。该研究有 83% 的应计率、6.6% 的提前退出率和 17% 的总流失率。化疗前患者报告的结果和客观评估的缺失评估分别为 27% 至 35% 和 35% 至 47%，在整个周期中普遍下降。每日日记完成率为 83%。参与者积极评价研究参与。

结论 

每日强化症状和功能监测对于 GC 患者是可行和可接受的，并且可以提供症状可控感。

对实践的启示 

研究中的日常症状和功能监测可以为患者提供信息，以支持与临床团队进行症状讨论。未来的工作应该使用个性化的症状轨迹开发积极的症状管理干预措施。